GlassScriptPhysician profile
Inna Kudria
NPI 1114970092
$9,047.86
in general payments reported to CMS, 2019-2025
45 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $425 · 2021: $852 · 2022: $995 · 2023: $1,243 · 2024: $1,837 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,978.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,173.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $772.24 | 2019-2025 | |
| Novo Nordisk INC | $747.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $591.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.04 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $498.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $417.36 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $416.43 | 2021-2025 | Veozah |
| Lilly USA, LLC | $352.20 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Merck Sharp & Dohme LLC | $293.95 | 2019-2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $291.50 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $257.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $233.68 | 2019-2024 | |
| Dexcom, INC. | $232.31 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $231.39 | 2020-2025 | Nexletol |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Kudria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.